Supreme Court denies United Therapeutics' certiorari; Liquidia's '793 patent invalid final

Liquidia Corp

Supreme Court rejected UTHR's cert petition, finalizing PTAB and Federal Circuit rulings that all claims of U.S. Patent No. 10,716,793 are invalid.
No valid claims of the three patents originally asserted by UTHR found infringed; all decisions final and not subject to further appeal.
FDA granted tentative approval of YUTREPIA for PAH and PH-ILD on Aug 16, 2024; final approval may occur after May 23, 2025.
U.S. District Court denied UTHR's preliminary injunction on '327 patent; trial scheduled for June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.